BNP Paribas Financial Markets Raises Holdings in Celcuity Inc. (NASDAQ:CELC)

BNP Paribas Financial Markets grew its stake in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 2,083.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,110 shares of the company's stock after buying an additional 43,044 shares during the period. BNP Paribas Financial Markets owned 0.12% of Celcuity worth $673,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Samlyn Capital LLC increased its holdings in Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock worth $21,735,000 after acquiring an additional 637,190 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Celcuity by 226.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company's stock worth $3,305,000 after purchasing an additional 153,712 shares during the period. Driehaus Capital Management LLC raised its position in shares of Celcuity by 62.3% in the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company's stock worth $3,351,000 after buying an additional 78,525 shares in the last quarter. Marshall Wace LLP boosted its stake in Celcuity by 40.0% during the second quarter. Marshall Wace LLP now owns 152,291 shares of the company's stock valued at $2,495,000 after buying an additional 43,476 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Celcuity by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 73,026 shares of the company's stock valued at $1,089,000 after buying an additional 18,809 shares during the period. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Stock Performance

NASDAQ CELC traded down $0.09 on Friday, reaching $12.52. 114,598 shares of the company's stock traded hands, compared to its average volume of 274,980. Celcuity Inc. has a 12 month low of $11.51 and a 12 month high of $22.19. The stock has a 50-day simple moving average of $14.39 and a 200 day simple moving average of $15.50. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CELC shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 price target on shares of Celcuity in a report on Friday, November 15th. Stifel Nicolaus raised their target price on shares of Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They set an "outperform" rating and a $27.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Celcuity has an average rating of "Buy" and a consensus target price of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.